Lonza Takes More Restructuring Steps | Chemical & Engineering News
Volume 91 Issue 30 | p. 18 | Concentrates
Issue Date: July 29, 2013

Lonza Takes More Restructuring Steps

Department: Business
Keywords: biosimilars, biologics, wood treatment

The Swiss fine chemicals producer Lonza is continuing the restructuring process begun by new CEO Richard Ridinger. The company is ending a joint venture with Teva Pharmaceutical Industries to develop so-called biosimilar biologic drugs, saying the process will cost more than initially planned. Lonza is also closing its microbial biologics manufacturing plant in Hopkinton, Mass., and consolidating microbial operations in Visp, Switzerland. And the firm says it will consider selling the wood treatment chemicals business it acquired with its 2011 purchase of Arch Chemicals.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment